Knowledge of human papillomavirus (HPV) and the HPV vaccine in a national sample of Australian men and women

Sexual Health ◽  
2010 ◽  
Vol 7 (3) ◽  
pp. 299 ◽  
Author(s):  
Marian K. Pitts ◽  
Wendy Heywood ◽  
Richard Ryall ◽  
Anthony M. Smith ◽  
Julia M. Shelley ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Genital Warts ◽  
National Sample ◽  
Vaccination Program ◽  
Men And Women ◽  
Pap Tests ◽  
Hpv Knowledge ◽  
Abnormal Pap Tests

Background: Human papillomavirus (HPV) knowledge has rarely been investigated in the context of a national vaccination program. The present study investigated HPV knowledge after the introduction of a national HPV vaccination program in Australia using a national sample of men and women. Methods: Questions assessing HPV knowledge were part of a broader national study of health and relationships administered via a computer-assisted telephone interview. These findings are from wave four of the study, conducted between 2007 and 2008. Knowledge questions about HPV included its association with cervical cancer, genital warts and abnormal Pap tests. Results: A total of 2634 women and 2556 men between the ages of 18 and 70 were interviewed. Overall, 62.8% (95% confidence interval (CI): 60.8–64.7%) of women and 38.3% (95% CI: 36.3–40.4%) of men had heard of HPV. Of these, 66.0% (95% CI: 64.1–67.9%) correctly answered that HPV is associated with cervical cancer, 50.2% (95% CI: 48.2–52.1%) answered that HPV is associated with abnormal Pap tests and 44.5% (95% CI: 42.5–46.5%) answered that HPV causes warts. Predictors of good knowledge included being female, aged between 26 and 45, holding higher education levels and older age at first sex. Ever having a Pap test was also associated with awareness about HPV. Conclusion: One of the highest levels of knowledge about HPV in Australia to date is reported in the present study. Knowledge about the association between HPV and cervical cancer was particularly high, especially when compared with knowledge of the association with genital warts. This appears to be a consequence of the marketing of the HPV vaccine as a vaccination against cervical cancer.

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program

Sexual Health ◽  
2007 ◽  
Vol 4 (3) ◽  
pp. 165 ◽  
Author(s):  
Shalini Kulasingam ◽  
Luke Connelly ◽  
Elizabeth Conway ◽  
Jane S. Hocking ◽  
Evan Myers ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Hpv Vaccine ◽  
Screening Program ◽  
Herd Immunity ◽  
Vaccination Program ◽  
Catch Up ◽  
The Cost ◽  
Current Screening

Background: The cost-effectiveness of adding a human papillomavirus (HPV) vaccine to the Australian National Cervical Screening Program compared to screening alone was examined. Methods: A Markov model of the natural history of HPV infection that incorporates screening and vaccination was developed. A vaccine that prevents 100% of HPV 16/18-associated disease, with a lifetime duration of efficacy and 80% coverage offered through a school program to girls aged 12 years, in conjunction with current screening was compared with screening alone using cost (in Australian dollars) per life-year (LY) saved and quality-adjusted life-year (QALY) saved. Sensitivity analyses included determining the cost-effectiveness of offering a catch-up vaccination program to 14–26-year-olds and accounting for the benefits of herd immunity. Results: Vaccination with screening compared with screening alone was associated with an incremental cost-effectiveness ratio (ICER) of $51 103 per LY and $18 735 per QALY, assuming a cost per vaccine dose of $115. Results were sensitive to assumptions about the duration of vaccine efficacy, including the need for a booster ($68 158 per LY and $24 988 per QALY) to produce lifetime immunity. Accounting for herd immunity resulted in a more attractive ICER ($36 343 per LY and $13 316 per QALY) for girls only. The cost per LY of vaccinating boys and girls was $92 052 and the cost per QALY was $33 644. The cost per LY of implementing a catch-up vaccination program ranged from $45 652 ($16 727 per QALY) for extending vaccination to 14-year-olds to $78 702 ($34 536 per QALY) for 26-year-olds. Conclusions: These results suggest that adding an HPV vaccine to Australia’s current screening regimen is a potentially cost-effective way to reduce cervical cancer and the clinical interventions that are currently associated with its prevention via screening alone.

scholarly journals Knowledge and Attitudes of a Cohort of Male University Students in Jamaica Regarding Human Papilloma Virus (HPV) and the HPV Vaccine

2016 ◽  
Vol 2 (3_suppl) ◽  
pp. 72s-73s
Author(s):  
Sean Parkinson ◽  
Ian Bambury ◽  
Carole Rattray
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Human Papilloma Virus ◽  
Disease Control ◽  
Hpv Vaccine ◽  
Genital Warts ◽  
Papilloma Virus ◽  
Knowledge And Attitudes ◽  
Control And Prevention ◽  
Male University Students

Abstract 51 Background: Cervical cancer is the second most common cancer in Jamaica with an incidence of 17.4/100,000. (1). Cervical cancer is acquired sexually, with the human papilloma virus (HPV) being the most important causative agent (2,3). HPV infection is associated with the development of other cancers such as anogenital, vaginal, vulvar and anal cancers in women, and penile and anal cancers in men.(2) It is also responsible for genital warts and oropharyngeal cancer in both men and women. Two vaccines were approved for the prevention of cervical cancer by the Food and Drug Administration (FDA) and are available in Jamaica (4,5). This study assessed the knowledge and attitudes in a male cohort towards HPV and HPV vaccine. Methods: This was a cross-sectional study in which two hundred male students were recruited. Information for this study was gathered from responses given in a self-administered questionnaire. Data was analyzed using the statistical package for social sciences (SPSS) version 20. Results: The mean age of the respondents was 22.6 years. 50.5% stated that they had heard of HPV. Of those who knew of the HPV, only 37.6% vs 39.6% of respondents reported that sexual intercourse was a requirement for HPV transmission, while 22.8% did not know. 43% reported knowing that HPV causes genital warts and 42% knew of an association with cervical cancer. 16.5% of the respondents knew of the HPV vaccine. Only 21.2% knew that the HPV vaccine protects against cervical cancer while the remaining 78.8% either said that it didn't provide protection or did not know. 15.3% knew that the vaccine is approved for both males and females while 84.7% did not know. Conclusion: There was significant knowledge deficit in the awareness of HPV and the HPV vaccine in our male university students. Gibson, T.N., et al., Age-specific incidence of cancer in Kingston and St. Andrew, Jamaica, 2003-2007. West Indian Med J, 2010. 59(5): p. 456-64. Centers for Disease Control and Prevention. Basic information about HPV –associated cancers. Available at: http://www.cdc.gov/cancer/hpv/basic_info . 2013. Bosch, F.X. and S. de Sanjose, Chapter 1: Human papillomavirus and cervical cancer-- burden and assessment of causality. J Natl Cancer Inst Monogr, 2003(31): p. 3-13. FDA licensure of bivalent Human Papillomavirus vaccine (HPV2,Cervarix) for use in females and updated vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) .Centers For Disease Control and Prevention (CDC). MMWR Morb Mort Wkly Rep, 2010(59): p. 626-9. FDA, “FDA Approves New Vaccine Indication for Gardasil to Prevent Genital Warts in Men and Boys,” Bethesda, Md, USA. 2009. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: No COIs from the authors.

Comparison of Knowledge and Attitudes Toward Human Papillomavirus, HPV Vaccine, Pap Tests, and Cervical Cancer Between US and Peruvian Women

2012 ◽  
Vol 16 (2) ◽  
pp. 121-126 ◽  
Author(s):  
Chi-Son Han ◽  
Daron G. Ferris ◽  
Jennifer Waller ◽  
Philip Tharp ◽  
Jessica Walter ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Pap Tests ◽  
Knowledge And Attitudes

The incidence of genital warts in Australian women prior to the national vaccination program

Sexual Health ◽  
2009 ◽  
Vol 6 (3) ◽  
pp. 178 ◽  
Author(s):  
Julia M. L. Brotherton ◽  
Anita Heywood ◽  
Stella Heley
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Surveillance System ◽  
Hpv Vaccination ◽  
Genital Warts ◽  
Recurrent Respiratory Papillomatosis ◽  
Vaccination Program

The quadrivalent human papillomavirus (HPV) vaccine currently being delivered to Australian women aged 12–26 years under the National HPV Vaccination Program promises to substantially reduce the incidence of genital warts. We review what is known about the burden of genital warts among Australian women. Incidence appears to peak among women aged 20–24 years, of whom 1.4% report genital warts in the previous year and who are hospitalised for treatment at a rate of 26 per 100 000. A surveillance system capable of documenting any decrease in the incidence of genital warts and recurrent respiratory papillomatosis after vaccination is urgently required.

scholarly journals Alaska Native adolescent views on cervical cancer, the human papillomavirus (HPV), genital warts and the quadrivalent HPV vaccine

2011 ◽  
Vol 70 (3) ◽  
pp. 245-253 ◽  
Author(s):  
Melissa Kemberling ◽  
Kyla Hagan ◽  
Jessica Leston ◽  
Sassa Kitka ◽  
Ellen Provost ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Alaska Native ◽  
Hpv Vaccine ◽  
Genital Warts ◽  
Quadrivalent Hpv Vaccine

scholarly journals Stakeholders’ Understandings of Human Papillomavirus (HPV) Vaccination in Sub-Saharan Africa: A Rapid Qualitative Systematic Review

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 496
Author(s):  
Caroline Deignan ◽  
Alison Swartz ◽  
Sara Cooper ◽  
Christopher J. Colvin
Keyword(s):  
Systematic Review ◽  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Sub Saharan Africa ◽  
African Countries ◽  
Qualitative Systematic Review ◽  
Sub Saharan ◽  
And Gender

Cervical cancer rates in Sub-Saharan Africa (SSA) are amongst the highest worldwide. All three of the Human Papillomavirus (HPV) vaccines (9-valent, quadrivalent and bivalent HPV vaccine) provide primary protection against the most common cancer-causing strains of HPV (types 16 and 18) that are known to cause 70% of cervical cancers. Over the last five years, there has been an increase in Sub-Saharan African countries that have introduced the HPV vaccine. The majority of research has been conducted on supply-side barriers and facilitators to HPV vaccination uptake in SSA, yet little research has been conducted on demand-side or end-user perspectives of, and decisions around, HPV vaccination. In order to complement existing research, and inform current and future HPV vaccination implementation approaches, this qualitative systematic review explored Stakeholders’ understandings of HPV vaccination in SSA. This review searched the following databases: Embase (via Scopus), Scopus, MEDLINE (via PubMed), PubMed, EBSCOhost, Academic Search Premier, Africa-Wide Information, CINAHL, PsycARTICLES, PsycINFO, SocINDEX, Web of Science, and the Cochrane Controlled Register of Trials (CENTRAL) and found a total of 259 articles. Thirty-one studies were found eligible for inclusion and were analyzed thematically using Braun and Clarke’s methods for conducting a thematic analysis. The quality of included studies was assessed using the Critical Appraisal Skills Programme (CASP) checklist. Three major themes emerged from this analysis; knowledge of HPV vaccination and cervical cancer is intertwined with misinformation; fear has shaped contradictory perceptions about HPV vaccination and gender dynamics are relevant in how stakeholders understand HPV vaccination in SSA.

scholarly journals Predictors of Human Papillomavirus Vaccine uptake or intent among parents of preadolescents and adolescents

2017 ◽  
Vol 7 (6) ◽  
pp. 35 ◽  
Author(s):  
Kimberlee Dayal ◽  
Sarah Robinson ◽  
Jessica Schoening ◽  
Mary Catherine Smith ◽  
Son Chae Kim
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Parental Education ◽  
Hpv Vaccination ◽  
College Education ◽  
Vaccine Effectiveness ◽  
Vaccine Uptake ◽  
Human Papillomavirus Vaccine ◽  
Hpv Knowledge ◽  
Hpv Vaccine Uptake

Aim: The aim of this study was to examine predictors of human papillomavirus (HPV) vaccine uptake or intent among parents of pre-adolescents and adolescents.Methods: A cross-sectional descriptive study was conducted among parents of girls aged 9 to 18 years, visiting two primary care clinics in central Texas from September to November 2015. Pearson’s product-moment correlation procedures and path analyses based on Health Belief Model were performed.Results: Path analysis showed that provider recommendation for HPV vaccination (β = 0.37; p < .001) and perceived HPV vaccine harm (β = -0.48; p < .001) had statistically significant direct effects on HPV vaccine uptake or intent. The perceived HPV vaccine effectiveness was directly influenced by HPV knowledge (β = 0.39; p < .001), empowerment in parent-provider relationships (β = 0.30; p = .006) and parental college education (β = 0.23; p = .039).}Conclusions: Together with parental empowerment fostering an equal partnership with providers, targeted education to improve parental HPV knowledge may convince them of the HPV vaccine effectiveness. This, in turn, may help them put the perceived HPV vaccine harm in proper perspective and allow them to make informed decisions regarding the timely HPV vaccination of their children. Because provider recommendation is one of the most important contributing factors for HPV vaccine uptake or intent, parental education and recommendations from nurses will help reduce the knowledge gaps and empower parents to make the timely decisions to vaccinate their children.

scholarly journals P5-S3.04 Continued decline in genital warts 3 years after introduction of quadrivalent Human papillomavirus (HPV) vaccination program

2011 ◽  
Vol 87 (Suppl 1) ◽  
pp. A321-A321
Author(s):  
T. Read ◽  
J. Hocking ◽  
L. Gurrin ◽  
M. Chen ◽  
B. Donovan ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Genital Warts ◽  
Vaccination Program

scholarly journals Evidence that HPV vaccine may be effective in preventing cervical cancer

2004 ◽  
Vol 8 (48) ◽  
Author(s):  
◽  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
North America ◽  
Hpv Vaccine ◽  
Controlled Trial ◽  
Double Blind ◽  
Highly Effective

Recently published results of a randomised, double-blind, multi-centre, placebo-controlled trial involving 1113 women from North America and Brazil indicate that a vaccine against the two most common human papillomavirus types causing cervical cancer, is highly effective

Sign in / Sign up

Export Citation Format

Share Document